
Liked By
Spread the love. Be the first to like this post!
Recent ANVS News
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 02/08/2023 10:12:56 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/20/2023 10:44:43 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/20/2023 10:43:38 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/20/2023 10:41:48 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/20/2023 10:41:47 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/20/2023 10:40:33 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/06/2023 09:06:37 PM
- Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team • PR Newswire (US) • 01/06/2023 12:30:00 PM
- Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update • PR Newswire (US) • 11/08/2022 10:35:00 PM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 11/08/2022 09:45:41 PM
- Annovis Bio to Present at the 2022 ThinkEquity Investor Conference • PR Newswire (US) • 10/20/2022 11:30:00 AM
- Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease • PR Newswire (US) • 10/11/2022 11:30:00 AM
- H.C. Wainwright Sticks to Its Buy Rating for Annovis Bio (ANVS) • TipRanks • 10/11/2022 08:46:40 AM
- Annovis Bio Shares Rise 6% After FDA Approves Buntanetap Study • Dow Jones News • 10/06/2022 02:34:00 PM
- Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease • PR Newswire (US) • 10/06/2022 11:30:00 AM
- Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference • PR Newswire (US) • 09/29/2022 11:30:00 AM
- Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases • PR Newswire (US) • 09/13/2022 11:30:00 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 09/12/2022 09:10:14 PM
- Annovis Bio's CEO Maria Maccecchini Issues Letter to Stockholders • PR Newswire (US) • 09/08/2022 11:30:00 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 08/30/2022 10:05:03 AM
- Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer • PR Newswire (US) • 08/29/2022 08:00:00 PM
- Annovis Bio (ANVS) Gets a Buy from Maxim Group • TipRanks • 08/25/2022 01:45:21 PM
- Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease • PR Newswire (US) • 08/24/2022 11:30:00 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 08/08/2022 12:31:32 PM
- Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update • PR Newswire (US) • 08/08/2022 11:30:00 AM
FEATURED Nextech3D.ai Enters Asian Market with Major 3D Modeling Deal to Revolutionize E-Commerce • Mar 30, 2023 10:00 AM
ARway Secures Multiple New SDK Deals to Drive Growth in $44B Indoor Positioning and Navigation Market • ARWYF • Mar 30, 2023 10:30 AM
OMID Posts 2022 Annual Report and Provides Update • OMID • Mar 30, 2023 9:15 AM
ReoStar Energy Corporation Acquires Interest in Emerging Global Iron Ore Producer Leuffer Mining Group • REOS • Mar 30, 2023 9:05 AM
Chilco River Holdings Announces Acquisition of L. Myers Associates • CRVH • Mar 30, 2023 9:00 AM
Alliance Creative Group (ACGX) Reports Revenue of $3,399,008 for Fourth Quarter of 2022 • ACGX • Mar 30, 2023 8:30 AM